MedTrace Logo

Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine

NCT01211028 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-05-11

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with expanded adipose derived stroma/stem cells sue, administered intramuscularly in patients with critical leg ischemia.

Conditions

Interventions

BIOLOGICAL

Expanded autologous ASCs

Drug: Expanded autologous adipose-derived adult stroma/stem cells

Sponsors & Collaborators

  • French Blood Establishment

    collaborator OTHER

  • Clinical Research Center, Toulouse

    collaborator OTHER

  • Centre National de la Recherche Scientifique, France

    collaborator OTHER

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Alessandra BURA-RIVIERE, Pr · University Hospital of Toulouse, Rangueil

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01211028 on ClinicalTrials.gov